We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.
About Us
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and strive to deliver superior business results. Mercury Pharmaceuticals thrives to maintain an environment built on mutual respect and individual integrity. This includes our customers we serve, employees, shareholders, partners, suppliers and communities.
Mercury Pharmaceuticals manufacturing solutions include contract biomanufacturing services, bioprocess development and purification equipment.
We have unique manufacturing capabilities and a track record for viruses and viral vectors (lentivirus, AAV, ADV, etc.) for gene therapy and vaccination, and experience in manufacturing monoclonal antibodies including: conjugation, mAb fragments and other rec-proteins from fermentation and cell culture for a broad range of therapeutic indications. We can also provide you with purification process development, along with preparative and industrial purification equipment for biologic and small biomolecule manufacturing including LPLC, continuous chromatography, and tailor-made TFF systems.
With history in traditional medicine, we have developed several drug products isolated from plant extracts.
Our Team
We are always thriving to maintain on our core values at Mercury Pharmaceuticals, we embrace the principles of good corporate governance, implemented through strong, independent and diverse membership on our team. We are consistently implementing the best governance practices, it is more important than ever that we continually earn our investor's confidence. We will do this by remaining a leader in corporate governance and providing clear, consistent and truthful communication about our performance.
> Meet the minds behind our innovations:
RANDALL JOHNSTON, PhD Chief Executive Officer at Mercury Pharmaceuticals
STEVE H. JORDAN, PhDChief Innovation Officer at Mercury Pharmaceuticals
MENDEL GREEN, (PhD, MSc, MPH)Senior Consultant/Researcher at Mercury Pharmaceuticals
Evelyn BecksChief Operating Officer at Mercury Pharmaceuticals
Paul Clarke, PhD
Chief Scientific Officer at Mercury Pharmaceuticals
Eleonora OrdunaPresident, Manufacturing Operations at Mercury Pharmaceuticals
Vihaan ReddyPresident, Oncology at Mercury Pharmaceuticals
Mik VelaChief Purchasing Officer at Mercury Pharmaceuticals
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care. - Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported. - Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency. - Learn more
Researchers found that feedback indicating participants had earned their favorite candy elicited a neural reward response practically equivalent to that of earning money. The findings may inform the design of financial incentives to encourage healthier eating, although further research is needed to establish whether these neural responses influence dietary behavior.
A randomized clinical trial involving 651 adults found that structured digital delivery of Alzheimer's disease genetic risk results was noninferior to clinician-led telehealth sessions in terms of knowledge, anxiety, and disease-specific distress. Participants also experienced similar psychological outcomes following blood biomarker disclosure, although satisfaction with genetic result disclosure was higher among those who received clinician-led counseling.
Patients with multiple myeloma who developed a serious gastrointestinal side effect after treatment with chimeric antigen receptor (CAR) T cell therapy had significantly more CAR T cells persisting in their blood stream, according to new research from The University of Texas MD Anderson Cancer Center.
A study led by Queen Mary University of London has found that the number of new cancer cases each year among transgender and gender-diverse people in England could more than double over the next decade.